Get the Stockscreener App
1.11
1.77%
-0.02
Citius Oncology Inc stock is traded at $1.11, with a volume of 1.58M.
It is down -1.77% in the last 24 hours and down -37.99% over the past month.
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
See More
Previous Close:
$1.13
Open:
$1.15
24h Volume:
1.58M
Relative Volume:
6.40
Market Cap:
$91.45M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-11.20%
1M Performance:
-37.99%
6M Performance:
+26.78%
1Y Performance:
+13.74%
1-Day Range:
$1.07
$1.2076
1-Week Range:
$1.07
$1.36
52-Week Range:
$0.5506
$6.19
Citius Oncology Inc Stock (CTOR) Company Profile
Name
Citius Oncology Inc
Sector
Phone
(908) 967-6677
Address
11 COMMERCE DRIVE, CRANFORD
Compare CTOR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTOR
Citius Oncology Inc
|
1.095 | 94.37M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
118.95 | 51.07B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.30 | 44.42B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.83 | 42.75B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.45 | 27.86B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
472.58 | 20.44B | 3.08B | 1.24B | 1.07B | 25.61 |
Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-23-25 | Upgrade | Maxim Group | Hold → Buy |
| Nov-27-24 | Initiated | Maxim Group | Buy |
Citius Oncology Inc Stock (CTOR) Latest News
Citius Oncology stock soars on expanded AI collaboration for LYMPHIR launch - Investing.com
Citius Oncology to advance LYMPHIR launch with AI technology - Investing.com India
Citius Oncology (Nasdaq: CTOR) taps Verix AI to support Q4 2025 LYMPHIR CTCL launch - Stock Titan
Is Citius Oncology Inc. stock attractive after correctionQuarterly Market Review & Fast Gaining Stock Reports - newser.com
Citius Oncology Inc.’s volatility index tracking explainedWeekly Stock Recap & Safe Investment Capital Preservation Plans - newser.com
Will Citius Oncology Inc. stock rally after Fed decisionsWeekly Gains Report & Verified Momentum Stock Alerts - newser.com
Will Citius Oncology Inc. stock keep outperforming rivals2025 Growth vs Value & Weekly Chart Analysis and Trade Guides - newser.com
Using Bollinger Bands to evaluate Citius Oncology Inc.2025 Stock Rankings & Free AI Powered Buy and Sell Recommendations - newser.com
How Citius Oncology Inc. stock compares to market leadersPortfolio Growth Summary & Weekly Breakout Watchlists - newser.com
Is Citius Oncology Inc. stock supported by innovation pipeline2025 Price Momentum & Short-Term Trading Alerts - newser.com
Will Citius Oncology Inc. stock deliver strong dividend growth2025 Volatility Report & Community Shared Stock Ideas - newser.com
How Citius Oncology Inc. stock reacts to oil pricesWeekly Volume Report & Weekly High Conviction Ideas - newser.com
What the charts say about Citius Oncology Inc. today2025 Historical Comparison & Momentum Based Trading Signals - newser.com
Why Citius Oncology Inc. stock is a value investor pickJuly 2025 EndofMonth & Fast Entry High Yield Stock Tips - newser.com
What data driven models say about Citius Oncology Inc.’s futureJuly 2025 Sector Moves & Real-Time Market Sentiment Alerts - newser.com
News impact scoring models applied to Citius Oncology Inc.Earnings Overview Summary & AI Forecast Swing Trade Picks - newser.com
Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences - Lelezard
Citius Oncology Inc Stock (CTOR) Financials Data
There is no financial data for Citius Oncology Inc (CTOR). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.58%
0.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):